GSK - Aurinia And Voclosporin In Lupus Nephritis: The Countdown Begins
The Need
The upcoming milestone at Aurinia Pharmaceuticals (AUPH), starting in Q4/2019, is the Phase 3 data readout for the Lupus Nephritis ((LN)) trial that could validate voclosporin (formerly ISA247) as first-line therapy in adjunct with steroids for LN. Meaning that voclosporin could be the first FDA-approved therapeutics for LN, a kidney disease that is triggered by the autoimmune disease, systemic lupus erythematosus ((SLE)).
Voclosporin is a structural analog of the calcineurin inhibitor, cyclosporin A, that has been pharmacologically altered to exert a more potent and greater immunosuppressive and anti-inflammatory effects over